GENinCode Plc (LON:GENI – Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as GBX 0.76 and last traded at GBX 0.80, with a volume of 5847561 shares trading hands. The stock had previously closed at GBX 0.85.
GENinCode Stock Down 6.5%
The firm has a market capitalization of £5.99 million, a PE ratio of -0.38 and a beta of 0.59. The business’s fifty day moving average price is GBX 1 and its 200 day moving average price is GBX 1.24. The company has a quick ratio of 15.88, a current ratio of 0.93 and a debt-to-equity ratio of 117.74.
GENinCode (LON:GENI – Get Free Report) last released its quarterly earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share (EPS) for the quarter. The company had revenue of GBX 308 million for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%. On average, equities research analysts forecast that GENinCode Plc will post -7.1299999 earnings per share for the current fiscal year.
GENinCode Company Profile
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.
See Also
- Five stocks we like better than GENinCode
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
- 3 Energy Stocks Racing to Fix AI’s Power Problem
Receive News & Ratings for GENinCode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENinCode and related companies with MarketBeat.com's FREE daily email newsletter.
